TP53 Gene Pro72Arg (rs1042522) Single Nucleotide Polymorphism As Not a Risk Factor for Colorectal Cancer in the Iranian Azari Population

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2017 Dec 30

PMID 29286614

Citations 13

Authors

Milad Asadi

Dariush Shanehbandi

Armin Zarintan

Negar Pedram

Behzad Baradaran

Venus Zafari

Masoud Shirmohamadi

Shahriyar Hashemzadeh

Affiliations

Soon will be listed here.

Abstract

Background: The p53 protein participates critically in several cellular functions such as cell growth and DNA repair. Polymorphisms in the TP53 locus have repeatedly been implicated in the pathogenesis of cancers all over the world. Over 200 single nucleotide polymorphisms (SNPs) have been characterized, but one well-known example at at codon 72, Pro72Arg (rs1042522), has the displayed inconsistent results with regard to cancer risk. Herein, we aimed to evaluate whether Pro72Arg (rs1042522) single nucleotide polymorphism (SNP) in TP53 gene might be associated with risk of colorectal cancer in the Iranian Azari population. Methods: Blood samples were taken from 100 healthy controls and 100 colorectal cancer patients with Iranian-Azeri ethnicity. Genotyping was performed with Tetra-ARMS PCR. Results: The alleles of the TP53 gene Pro72Arg SNP did not significantly differ in prevalence between patients and controls (P>0.05). Additionally, genotypes of Pro72Arg SNP were not significantly associated with colorectal cancer risk in the studied population. Conclusions: Pro72Arg SNP of TP53 gene may not be involved in the disease pathogenesis in Iranian Azari patients with colorectal cancer.

Citing Articles

Genetic polymorphisms in FABP2, CYP2E1, and TP53 genes are potentially associated with colorectal cancer susceptibility.

Ijaz M, Chen C, Iqbal R, Farooq H, Mehmood R, Asif M Sci Rep. 2024; 14(1):20464.

PMID: 39242607 PMC: 11379967. DOI: 10.1038/s41598-024-70381-y.

Low-Penetrance Susceptibility Variants in Colorectal Cancer-Current Outlook in the Field.

Szuman M, Kaczmarek-Rys M, Hryhorowicz S, Kryszczynska A, Grot N, Plawski A Int J Mol Sci. 2024; 25(15).

PMID: 39125905 PMC: 11313073. DOI: 10.3390/ijms25158338.

microRNAs Regulate Survivin in Colorectal Cancer Patients.

Chavoshi H, Bornehdeli S, Asadi M, Dolatkhah R, Caner A, Raeisi M Adv Biomed Res. 2023; 12:227.

PMID: 38073748 PMC: 10699232. DOI: 10.4103/abr.abr_233_22.

The Genomic Landscape of Colorectal Cancer in the Saudi Arabian Population Using a Comprehensive Genomic Panel.

Alsolme E, Alqahtani S, Fageeh M, Barakeh D, Sharma N, Mangul S Diagnostics (Basel). 2023; 13(18).

PMID: 37761360 PMC: 10527739. DOI: 10.3390/diagnostics13182993.

Absence of GSTT1 and polymorphisms in GSTP1 and TP53 are associated with the incidence of acne vulgaris.

Ullah R, Afgan S, Akhtar M, Asif M, Latif M, Mehmood R Skin Res Technol. 2023; 29(4):e13333.

PMID: 37113088 PMC: 10234175. DOI: 10.1111/srt.13333.

References

Zhu Z, Wang A, Jia H, Jin X, He X, Hou L . Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol. 2007; 37(5):385-90. DOI: 10.1093/jjco/hym034. View

Siddique M, Sabapathy K . Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene. 2006; 25(25):3489-500. DOI: 10.1038/sj.onc.1209405. View

Soussi T, Beroud C . Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 2002; 1(3):233-40. DOI: 10.1038/35106009. View

Ye S, Dhillon S, Ke X, Collins A, Day I . An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res. 2001; 29(17):E88-8. PMC: 55900. DOI: 10.1093/nar/29.17.e88. View

Rupnarain C, Dlamini Z, Naicker S, Bhoola K . Colon cancer: genomics and apoptotic events. Biol Chem. 2004; 385(6):449-64. DOI: 10.1515/BC.2004.053. View

Gomez-Lazaro M, Fernandez-Gomez F, Jordan J . p53: twenty five years understanding the mechanism of genome protection. J Physiol Biochem. 2005; 60(4):287-307. DOI: 10.1007/BF03167075. View

Whibley C, Pharoah P, Hollstein M . p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009; 9(2):95-107. DOI: 10.1038/nrc2584. View

Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G . Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999; 19(2):1092-100. PMC: 116039. DOI: 10.1128/MCB.19.2.1092. View

Zhu Z, Cong W, Liu S, Dong H, Zhu G, Wu M . Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J Gastroenterol. 2005; 11(2):289-92. PMC: 4205420. DOI: 10.3748/wjg.v11.i2.289. View

10.

Mahasneh A, Abdel-Hafiz S . Polymorphism of p53 gene in Jordanian population and possible associations with breast cancer and lung adenocarcinoma. Saudi Med J. 2004; 25(11):1568-73. View

11.

Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D . P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res. 2001; 7(5):1343-9. View

12.

Perez L, Abba M, Dulout F, Golijow C . Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol. 2006; 12(9):1426-9. PMC: 4124323. DOI: 10.3748/wjg.v12.i9.1426. View

13.

Pim D, Banks L . p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 2003; 108(2):196-9. DOI: 10.1002/ijc.11548. View

14.

Robles A, Harris C . p53-mediated apoptosis and genomic instability diseases. Acta Oncol. 2002; 40(6):696-701. DOI: 10.1080/02841860152619106. View

15.

Dumont P, Leu J, Della Pietra 3rd A, George D, Murphy M . The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003; 33(3):357-65. DOI: 10.1038/ng1093. View

16.

Miller S, Dykes D, Polesky H . A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16(3):1215. PMC: 334765. DOI: 10.1093/nar/16.3.1215. View

17.

Kalemi T, Lambropoulos A, Gueorguiev M, Chrisafi S, T Papazisis K, Kotsis A . The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett. 2005; 222(1):57-65. DOI: 10.1016/j.canlet.2004.11.025. View

18.

Noma C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S . Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett. 2004; 210(2):197-203. DOI: 10.1016/j.canlet.2004.03.031. View

19.

Lu X, Zhang Y, Lin R, Liang X, Zhang Y, Wang X . p53 polymorphism in human papillomavirus-associated Kazakh's esophageal cancer in Xinjiang, China. World J Gastroenterol. 2004; 10(19):2775-8. PMC: 4572100. DOI: 10.3748/wjg.v10.i19.2775. View

20.

Borresen-Dale A . TP53 and breast cancer. Hum Mutat. 2003; 21(3):292-300. DOI: 10.1002/humu.10174. View